Drug facts

Tirzepatide sold as a “research” powder

By David Chen·Editor·Reviewed November 2026

What “research use only” means¹

It means the seller is disclaiming the sale of a medicine while selling one. FDA addresses these products directly, under a heading of its own — “Versions sold falsely for research purposes or not for human consumption”:

FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled “for research purposes” or “not for human consumption.” These products have been sold directly to consumers for human use with dosing instructions. The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.

Three words in that paragraph carry it: falsely, illegally and unknown. FDA looks at how a seller markets and supplies a product. A research disclaimer does not override evidence that it is intended for human use, or establish its quality.

What FDA found on these sites²

This is not a general warning about a category. FDA reads the actual product pages and quotes them back. Three letters that name tirzepatide:

• USApeptide.com, February 2025 — tirzepatide and semaglutide offered with “research use only,” “not for human consumption” and “lab purposes only” on the labeling, while the product copy sold them for weight loss and diabetes. FDA also noted what the site sold alongside them: bacteriostatic water and packs of insulin syringes.
• Gram Peptides, March 2026 — tirzepatide listed on the site as “GLP-2 peptide”, beside retatrutide as “GLP-1-R peptide”, with the page claiming weight and lipid effects “in both animal and human studies.”³
• Royal Peptides LLC, August 2026 — tirzepatide vials, sold with the sentence FDA quoted from the site: “Once-weekly injection for convenience.” The same site offered a tirzepatide-and-retatrutide mixed kit.⁴

The Gram Peptides letter goes one step further than the product itself, and it is the step that matters for anyone searching for mixing instructions. FDA:

Your firm offers “Bacteriostatic Water for Injection” for sale alongside peptide products, which are drugs intended for injection and require reconstitution … The sale of these products together demonstrates that you intend for your “Bacteriostatic Water for Injection” to be used in combination for injection. Therefore, your “Bacteriostatic Water for Injection” is a drug.

The Royal Peptides letter names the tools as well. ⁴ FDA writes that the firm marketed bacteriostatic water “alongside a ‘peptide guide’ and ‘peptide calculator,’ resources that collectively provide the means to prepare an injectable drug for human administration.” A calculator, in FDA’s reading, is part of the evidence that a “research” product is really being sold for injection into people.

The disclaimer changes nothing²

FDA’s reasoning is the same in each letter:

Despite statements on your product labeling and website such as “research use only,” “not for human consumption,” “lab purposes only,” and “not intended to diagnose, cure, mitigate, treat or prevent disease,” evidence obtained from your website establishes that certain products offered for sale by www.usapeptide.com are drugs intended for human use.

What follows from that is the part worth understanding. Tirzepatide is a prescription drug, and FDA states why a prescription drug cannot be sold with usable instructions to a member of the public: because the drugs are

intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use.

That sentence is the legal definition of the gap these vials leave open. There is no set of instructions that makes a prescription-strength injectable safe to work out for yourself — which is why a page promising to close that gap with a volume and a syringe mark is promising something FDA says does not exist.

What is in the vial is unknown²

FDA’s summary of the risk in unapproved drugs bought this way: they “may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.” And because these are injections, the letters add that injectable products “bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.”³

That is not hypothetical about the ingredient supply. FDA has an import alert covering GLP-1 bulk drug substances, and it publishes what it found: of 48 GLP-1 ingredient sites it inspected or assessed, 21% were noncompliant with manufacturing requirements — either because their own records showed it or because they did not answer FDA at all. The alert also describes a pattern of firms that “register as GLP-1 API manufacturers, offer GLP-1 APIs for import, refuse to answer FDA’s requests for records, and then deregister, all within a short period of time.”⁵

Those sites at least register with FDA and sell to pharmacies, which is how the agency came to look at them. A research-use disclaimer gives a buyer no assurance that the ingredient source meets the requirements for human medicines.

A published laboratory check of no-prescription online GLP-1 purchases tested semaglutide, not tirzepatide, and is reported here as a semaglutide result. ⁹ Researchers bought from six illegal online pharmacies; three orders never arrived at all. In the three vials that did, measured purity ran from 7.7% to 14.37% against the 99% claimed on the labels, the amount of semaglutide exceeded the labeled amount by 28.56% to 38.69%, and endotoxin was detected in every sample. This study did not test tirzepatide. ¹⁰ Its measurements therefore cannot establish the contents of a tirzepatide vial.

The mixing arithmetic, and what it cannot fix⁶

The sum itself is short: milligrams in the vial divided by the milliliters of water added gives the concentration, and a dose divided by that concentration, times 100, is the mark on a U-100 syringe. The reconstitution calculator does it on the numbers you type, and it never supplies a volume or a dose of its own. Getting the sum right does not make the powder any less unknown.

No approved product has to be mixed. The Zepbound label, section 3, describes what the medicine is:

Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens.

A solution. It arrives mixed, at a strength a manufacturer set and FDA reviewed, in a container labeled with that strength. Nothing in the approved use of tirzepatide involves a patient adding water to a powder.

Compounded tirzepatide is not an exception to that, because the mixing is the pharmacist’s job by definition. FDA: ⁷

Compounding is generally a practice in which a licensed pharmacist, a licensed physician or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.

So in both legitimate routes, the person doing the arithmetic is licensed, accountable and working from a prescription written for one named patient. A research powder moves that job to the buyer, and moves it out of reach of everyone who would otherwise catch a mistake. The authors of a review of this trade put the practical problem plainly: these vials are sold ⁸

frequently without the supplies and knowledge they would need to dissolve the active ingredient, draw it up into a syringe, and inject it into the body.

Their review covered semaglutide and tirzepatide together, and names both. Arithmetic fills one of those gaps and none of the others: there is still no prescriber, no sterility testing and no way to know what the powder is. For a vial that came from a pharmacy with a label, tirzepatide dosage in units explains what the numbers on it mean.

What the licensed route looks like¹

FDA’s own instruction to patients is two lines long: obtain a prescription from your doctor, and fill it at a state-licensed pharmacy. The sellers this site tracks and their recorded pricing are on the price index. Before buying from any of them, four checks that take ten minutes covers the prescription, the pharmacy, its license and any FDA letter against it; what can still go wrong afterwards is in is compounded tirzepatide safe?

Nothing here is medical advice, and no volume of water or dose on this site is a recommendation. If you have already injected something from a vial like this, that is a conversation for a clinician today, not for a web page. Adverse events can be reported to FDA’s MedWatch program. See the medical disclaimer.